Küleon Biosciences

Küleon Biosciences is a biotechnology company dedicated to developing next-generation precision medicines for neurodevelopmental and neuropsychiatric disorders. The company leverages a proprietary drug discovery platform that integrates advanced human genetics, functional genomics, and medicinal chemistry to target validated CNS pathways. Their primary focus is on ion channels and G protein-coupled receptors (GPCRs) that play critical roles in neuronal excitability. Their lead programs focus on KCNQ2/3 potassium channel activators for the treatment of epilepsy and other hyperexcitability disorders. By focusing on genetically defined patient populations, Küleon aims to improve clinical outcomes and reduce the high failure rates traditionally associated with CNS drug development. The leadership team consists of industry veterans with extensive experience in neuroscience drug discovery from companies like Merck and Vertex.